

# Luis L Ostrosky-Zeichner

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4686312/publications.pdf>

Version: 2024-02-01

135  
papers

20,408  
citations

34105

52  
h-index

18647

119  
g-index

137  
all docs

137  
docs citations

137  
times ranked

13013  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical Practice Guidelines for the Management Candidiasis: 2009 Update by the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2009, 48, 503-535.	5.8	2,644
2	Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2016, 62, e1-e50.	5.8	2,489
3	Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. <i>Clinical Infectious Diseases</i> , 2020, 71, 1367-1376.	5.8	1,429
4	Executive Summary: Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2016, 62, 409-417.	5.8	1,258
5	Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. <i>Lancet</i> , The, 2007, 369, 1519-1527.	13.7	1,185
6	Micafungin versus Caspofungin for Treatment of Candidemia and Other Forms of Invasive Candidiasis. <i>Clinical Infectious Diseases</i> , 2007, 45, 883-893.	5.8	1,115
7	Multicenter Clinical Evaluation of the (1-&gt;3) $\beta$ -D-Glucan Assay as an Aid to Diagnosis of Fungal Infections in Humans. <i>Clinical Infectious Diseases</i> , 2005, 41, 654-659.	5.8	640
8	$\beta$ -D-Glucan as a Diagnostic Adjunct for Invasive Fungal Infections: Validation, Cutoff Development, and Performance in Patients with Acute Myelogenous Leukemia and Myelodysplastic Syndrome. <i>Clinical Infectious Diseases</i> , 2004, 39, 199-205.	5.8	610
9	Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. <i>Lancet Infectious Diseases</i> , The, 2021, 21, e149-e162.	9.1	586
10	Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 828-837.	9.1	528
11	Antifungal Susceptibility Survey of 2,000 Bloodstream <i>Candida</i> Isolates in the United States. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 3149-3154.	3.2	493
12	Combination Antifungal Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 693-715.	3.2	478
13	T2 Magnetic Resonance Assay for the Rapid Diagnosis of Candidemia in Whole Blood: A Clinical Trial. <i>Clinical Infectious Diseases</i> , 2015, 60, 892-899.	5.8	369
14	Defining Responses to Therapy and Study Outcomes in Clinical Trials of Invasive Fungal Diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer Consensus Criteria. <i>Clinical Infectious Diseases</i> , 2008, 47, 674-683.	5.8	368
15	An insight into the antifungal pipeline: selected new molecules and beyond. <i>Nature Reviews Drug Discovery</i> , 2010, 9, 719-727.	46.4	360
16	Amphotericin B: Time for a New "Gold Standard". <i>Clinical Infectious Diseases</i> , 2003, 37, 415-425.	5.8	350
17	Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2007, 26, 271-276.	2.9	325
18	Correlation between E-Test, Disk Diffusion, and Microdilution Methods for Antifungal Susceptibility Testing of Fluconazole and Voriconazole. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 1647-1651.	3.2	221

#	ARTICLE	IF	CITATIONS
19	Invasive candidiasis in the intensive care unit. <i>Critical Care Medicine</i> , 2006, 34, 857-863.	0.9	217
20	In Vitro Antifungal Susceptibilities of Trichosporon Species. <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 1144-1146.	3.2	184
21	Interlaboratory Comparison of Results of Susceptibility Testing with Caspofungin against Candida and Aspergillus Species. <i>Journal of Clinical Microbiology</i> , 2004, 42, 3475-3482.	3.9	174
22	Rules for identifying patients at increased risk for candidal infections in the surgical intensive care unit: approach to developing practical criteria for systematic use in antifungal prophylaxis trials. <i>Medical Mycology</i> , 2005, 43, 235-243.	0.7	165
23	Invasive Mycoses: Diagnostic Challenges. <i>American Journal of Medicine</i> , 2012, 125, S14-S24.	1.5	162
24	Open-Label, Randomized Comparison of Itraconazole versus Caspofungin for Prophylaxis in Patients with Hematologic Malignancies. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 143-147.	3.2	153
25	MSG-01: A Randomized, Double-Blind, Placebo-Controlled Trial of Caspofungin Prophylaxis Followed by Preemptive Therapy for Invasive Candidiasis in High-Risk Adults in the Critical Care Setting. <i>Clinical Infectious Diseases</i> , 2014, 58, 1219-1226.	5.8	142
26	Detecting Infections Rapidly and Easily for Candidemia Trial, Part 2 (DIRECT2): A Prospective, Multicenter Study of the T2Candida Panel. <i>Clinical Infectious Diseases</i> , 2018, 66, 1678-1686.	5.8	129
27	Intensive care medicine research agenda on invasive fungal infection in critically ill patients. <i>Intensive Care Medicine</i> , 2017, 43, 1225-1238.	8.2	123
28	Differences in beta-glucan levels in culture supernatants of a variety of fungi. <i>Medical Mycology</i> , 2006, 44, 267-272.	0.7	121
29	Isavuconazole Versus Caspofungin in the Treatment of Candidemia and Other Invasive Candida Infections: The ACTIVE Trial. <i>Clinical Infectious Diseases</i> , 2019, 68, 1981-1989.	5.8	120
30	Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria. <i>Diagnostic Microbiology and Infectious Disease</i> , 2011, 70, 330-343.	1.8	117
31	(1,3)- $\beta$ -D-Glucan as a Prognostic Marker of Treatment Response in Invasive Candidiasis. <i>Clinical Infectious Diseases</i> , 2012, 55, 521-526.	5.8	116
32	Invasive Candidiasis in Immunocompromised Hospitalized Patients. <i>Archives of Medical Research</i> , 2005, 36, 660-671.	3.3	105
33	Improvement of a clinical prediction rule for clinical trials on prophylaxis for invasive candidiasis in the intensive care unit. <i>Mycoses</i> , 2011, 54, 46-51.	4.0	98
34	Prospective Survey of (1 $\rightarrow$ 3)- $\beta$ -Glucan and Its Relationship to Invasive Candidiasis in the Surgical Intensive Care Unit Setting. <i>Journal of Clinical Microbiology</i> , 2011, 49, 58-61.	3.9	96
35	What's new in the clinical and diagnostic management of invasive candidiasis in critically ill patients. <i>Intensive Care Medicine</i> , 2014, 40, 808-819.	8.2	90
36	Core Recommendations for Antifungal Stewardship: A Statement of the Mycoses Study Group Education and Research Consortium. <i>Journal of Infectious Diseases</i> , 2020, 222, S175-S198.	4.0	83

#	ARTICLE	IF	CITATIONS
37	In Vitro Activity of Anidulafungin against Selected Clinically Important Mold Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 1912-1915.	3.2	82
38	Global guideline for the diagnosis and management of rare yeast infections: an initiative of the ECMM in cooperation with ISHAM and ASM. <i>Lancet Infectious Diseases</i> , The, 2021, 21, e375-e386.	9.1	80
39	Early treatment of candidemia in adults: a review. <i>Medical Mycology</i> , 2011, 49, 113-120.	0.7	78
40	In Vitro Synergy Testing of Anidulafungin with Itraconazole, Voriconazole, and Amphotericin B against <i>Aspergillus</i> spp. and <i>Fusarium</i> spp. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 3572-3574.	3.2	76
41	Rezafungin Versus Caspofungin in a Phase 2, Randomized, Double-blind Study for the Treatment of Candidemia and Invasive Candidiasis: The STRIVE Trial. <i>Clinical Infectious Diseases</i> , 2021, 73, e3647-e3655.	5.8	75
42	Coronavirus Disease 2019-associated Invasive Fungal Infection. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab510.	0.9	75
43	In Vitro Activities of Investigational Triazoles against <i>Fusarium</i> Species: Effects of Inoculum Size and Incubation Time on Broth Microdilution Susceptibility Test Results. <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 3298-3300.	3.2	74
44	Cost of a Ventilator-Associated Pneumonia in a Shock Trauma Intensive Care Unit. <i>Surgical Infections</i> , 2005, 6, 65-72.	1.4	74
45	New approaches to the risk of <i>Candida</i> in the intensive care unit. <i>Current Opinion in Infectious Diseases</i> , 2003, 16, 533-537.	3.1	73
46	Tigecycline: a critical safety review. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 335-342.	2.4	70
47	Current Options in Antifungal Pharmacotherapy. <i>Pharmacotherapy</i> , 2008, 28, 614-645.	2.6	68
48	Effects of Serum on In Vitro Susceptibility Testing of Echinocandins. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 4214-4216.	3.2	67
49	Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients. <i>JAMA Internal Medicine</i> , 2022, 182, 115.	5.1	63
50	Cefepime free minimum concentration to minimum inhibitory concentration (fCmin/MIC) ratio predicts clinical failure in patients with Gram-negative bacterial pneumonia. <i>International Journal of Antimicrobial Agents</i> , 2015, 45, 541-544.	2.5	58
51	Drugs in Clinical Development for Fungal Infections. <i>Drugs</i> , 2017, 77, 1505-1518.	10.9	58
52	Pharmacokinetic Evaluation of Single-Dose Intravenous Daptomycin in Patients with Thermal Burn Injury. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 1891-1893.	3.2	57
53	Deeply invasive candidiasis. <i>Infectious Disease Clinics of North America</i> , 2002, 16, 821-835.	5.1	55
54	MSG-10: a Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 3056-3062.	3.0	54

#	ARTICLE	IF	CITATIONS
55	Correlation of Clinical Outcomes with $\beta$ -Glucan Levels in Patients with Invasive Candidiasis. <i>Journal of Clinical Microbiology</i> , 2012, 50, 2104-2106.	3.9	51
56	Thinking beyond the Common Candida Species: Need for Species-Level Identification of Candida Due to the Emergence of Multidrug-Resistant <i>Candida auris</i> . <i>Journal of Clinical Microbiology</i> , 2017, 55, 3324-3327.	3.9	49
57	Invasive Fungal Infections in the Intensive Care Unit. <i>Infectious Disease Clinics of North America</i> , 2017, 31, 475-487.	5.1	49
58	Liposuction for protease-inhibitor-associated lipodystrophy. <i>Lancet</i> , The, 1999, 353, 1244.	13.7	47
59	Successful Use of Amphotericin B Lipid Complex in the Treatment of Cryptococcosis. <i>Clinical Infectious Diseases</i> , 2005, 40, S409-S413.	5.8	46
60	Invasive Candidiasis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2020, 41, 003-012.	2.1	45
61	Peritonitis due to <i>Aspergillus</i> and zygomycetes in patients undergoing peritoneal dialysis: report of 2 cases and review of the literature. <i>Diagnostic Microbiology and Infectious Disease</i> , 2003, 46, 49-54.	1.8	44
62	Editorial Commentary: <i>Candida glabrata</i> and FKS Mutations: Witnessing the Emergence of the True Multidrug-Resistant <i>Candida</i> . <i>Clinical Infectious Diseases</i> , 2013, 56, 1733-1734.	5.8	43
63	A Mycoses Study Group International Prospective Study of Phaeohyphomycosis: An Analysis of 99 Proven/Probable Cases. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx200.	0.9	43
64	In Vitro Activity of Nystatin Compared with Those of Liposomal Nystatin, Amphotericin B, and Fluconazole against Clinical <i>Candida</i> Isolates. <i>Journal of Clinical Microbiology</i> , 2002, 40, 1406-1412.	3.9	41
65	Rationale for Reading Fluconazole MICs at 24 Hours Rather than 48 Hours When Testing <i>Candida</i> spp. by the CLSI M27-A2 Standard Method. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 4175-4177.	3.2	40
66	Correlation between Microdilution, E-test, and Disk Diffusion Methods for Antifungal Susceptibility Testing of Posaconazole against <i>Candida</i> spp. <i>Journal of Clinical Microbiology</i> , 2006, 44, 2105-2108.	3.9	39
67	Clinical Characteristics and Predictors of Adverse Outcome in Adult and Pediatric Patients With Healthcare-Associated Ventriculitis and Meningitis. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw077.	0.9	39
68	Multilaboratory Testing of Two-Drug Combinations of Antifungals against <i>Candida albicans</i> , <i>Candida glabrata</i> , and <i>Candida parapsilosis</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 1543-1548.	3.2	38
69	Comparative effectiveness of echinocandins versus fluconazole therapy for the treatment of adult candidaemia due to <i>Candida parapsilosis</i> : a retrospective observational cohort study of the Mycoses Study Group (MSG-12): Table A1.. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 3536-3539.	3.0	37
70	Contemporary Treatment and Outcomes of Zygomycosis in a Non-oncologic Tertiary Care Center. <i>Archives of Medical Research</i> , 2007, 38, 90-93.	3.3	35
71	Neurocysticercosis and HIV infection: Report of two cases and review. <i>World Neurosurgery</i> , 1996, 45, 57-61.	1.3	34
72	Isavuconazole for treatment of rare invasive fungal diseases. <i>Mycoses</i> , 2018, 61, 518-533.	4.0	32

#	ARTICLE	IF	CITATIONS
73	Pharmacokinetics of Intravenous Itraconazole in Stable Hemodialysis Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 3151-3153.	3.2	31
74	Surveillance of <i>Candida</i> spp Bloodstream Infections: Epidemiological Trends and Risk Factors of Death in Two Mexican Tertiary Care Hospitals. <i>PLoS ONE</i> , 2014, 9, e97325.	2.5	30
75	Multilaboratory Testing of Antifungal Combinations against a Quality Control Isolate of <i>Candida krusei</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 1500-1502.	3.2	28
76	Effect of the Echinocandin Caspofungin on Expression of <i>Candida albicans</i> Secretory Aspartyl Proteinases and Phospholipase In Vitro. <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 3096-3100.	3.2	26
77	Associations between antibiotic use and changes in susceptibility patterns of in a private, university-affiliated teaching hospital: an 8-year-experience: 1995-2002. <i>International Journal of Antimicrobial Agents</i> , 2004, 24, 346-351.	2.5	26
78	Early antifungal intervention strategies in ICU patients. <i>Current Opinion in Critical Care</i> , 2010, 16, 465-469.	3.2	26
79	Syscan3, a Kit for Detection of Anti- <i>Candida</i> Antibodies for Diagnosis of Invasive Candidiasis. <i>Journal of Clinical Microbiology</i> , 2005, 43, 4834-4835.	3.9	25
80	Isavuconazole treatment for rare fungal diseases and for invasive aspergillosis in patients with renal impairment: Challenges and lessons of the VITAL trial. <i>Mycoses</i> , 2018, 61, 420-429.	4.0	25
81	Noninvasive Testing and Surrogate Markers in Invasive Fungal Diseases. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.9	25
82	Pharmacoeconomics of antifungal pharmacotherapy – challenges and future directions. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 2617-2632.	1.8	24
83	Isavuconazole for treatment of invasive fungal diseases caused by more than one fungal species. <i>Mycoses</i> , 2018, 61, 485-497.	4.0	24
84	Therapy of common superficial fungal infections. <i>Dermatologic Therapy</i> , 2004, 17, 517-522.	1.7	23
85	Fatal Amphotericin B Overdose Due to Administration of Nonlipid Formulation Instead of Lipid Formulation. <i>Pharmacotherapy</i> , 2005, 25, 426-428.	2.6	21
86	Investigational Agents for the Treatment of Resistant Yeasts and Molds. <i>Current Fungal Infection Reports</i> , 2021, 15, 104-115.	2.6	18
87	In Vitro Evaluation of BacT/Alert FA Blood Culture Bottles and T2Candida Assay for Detection of <i>Candida</i> in the Presence of Antifungals. <i>Journal of Clinical Microbiology</i> , 2018, 56, .	3.9	17
88	Seroprevalence of <i>Strongyloides stercoralis</i> and Evaluation of Universal Screening in Kidney Transplant Candidates: A Single-Center Experience in Houston (2012-2017). <i>Open Forum Infectious Diseases</i> , 2019, 6, .	0.9	17
89	Differential Antifungal Activity of Isomeric Forms of Nystatin. <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 2781-2786.	3.2	16
90	Clinical prediction rules for invasive candidiasis in the ICU: ready for prime time?. <i>Critical Care</i> , 2011, 15, 189.	5.8	15

#	ARTICLE	IF	CITATIONS
91	Impact of inappropriate antifungal therapy according to current susceptibility breakpoints on Candida bloodstream infection mortality, a retrospective analysis. BMC Infectious Diseases, 2017, 17, 753.	2.9	15
92	Povidone-iodine solution as SARS-CoV-2 prophylaxis for procedures of the upper aerodigestive tract a theoretical framework. Journal of Otolaryngology - Head and Neck Surgery, 2020, 49, 77.	1.9	15
93	The Role of In Vitro Susceptibility Testing in the Management of Candida and Aspergillus. Journal of Infectious Diseases, 2017, 216, S452-S457.	4.0	14
94	A Risk Score for Fluconazole Failure among Patients with Candidemia. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	12
95	Activity of Anidulafungin in a Murine Model of <i>Candida krusei</i> Infection: Evaluation of Mortality and Disease Burden by Quantitative Tissue Cultures and Measurement of Serum (1,3)- $\beta$ -D-Glucan Levels. Antimicrobial Agents and Chemotherapy, 2009, 53, 1639-1641.	3.2	11
96	Point-Counterpoint: Should Serum $\beta$ -D-Glucan Testing Be Used for the Diagnosis of Pneumocystis jirovecii Pneumonia?. Journal of Clinical Microbiology, 2019, 58, .	3.9	11
97	Progressive Dispersion of Azole Resistance in Aspergillus fumigatus: Fatal Invasive Aspergillosis in a Patient with Acute Myeloid Leukemia Infected with an A. fumigatus Strain with a <i>cyp51A</i> TR <sub>46</sub> Y121F M172I T289A Allele. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	10
98	Screening donors for COVID-19 convalescent plasma. Transfusion, 2021, 61, 1047-1052.	1.6	8
99	Systemic antifungal therapy with isavuconazonium sulfate or other agents in adults with invasive mucormycosis or invasive aspergillosis (non- <i>A. fumigatus</i> ): A multicentre, non-interventional registry study. Mycoses, 2022, 65, 186-198.	4.0	7

100

#	ARTICLE	IF	CITATIONS
109	Antifungal and Antiviral Therapy. , 2008, , 1089-1109.		2
110	Antifungal Susceptibility Testing: Evolution, Indications, and Role in Clinical Practice. Current Treatment Options in Infectious Diseases, 2015, 7, 155-162.	1.9	2
111	Epidemiology and Management of Candidiasis in Solid Organ Transplant Recipients. Current Fungal Infection Reports, 2016, 10, 147-152.	2.6	2
112	Anidulafungin: a new addition to the antifungal armamentarium. Therapy: Open Access in Clinical Medicine, 2007, 4, 125-132.	0.2	1
113	Neonatal Fungal Infections. , 2008, , 262-278.		1
114	Invasive Candidiasis in the Intensive Care Unit. Hospital Practice (1995), 2010, 38, 82-91.	1.0	1
115	High-Dose Caspofungin is Safe for Adult Patients with Invasive Candidiasis. Current Fungal Infection Reports, 2011, 5, 1-2.	2.6	1
116	369. Using Hybrid Models and Blockchain Technology as a Means to Develop a Novel Propensity Score for Candidemia and Invasive Candidiasis. Open Forum Infectious Diseases, 2018, 5, S144-S145.	0.9	1
117	Reprocessing N95s with hydrogen peroxide vaporization: A robust system from collection to dispensing. American Journal of Infection Control, 2021, 49, 508-511.	2.3	1
118	Candidemia: An Infection Prevention Issue?. Clinical Infectious Diseases, 2021, 73, 697-698.	5.8	1
119	Furuncular myiasis in a traveller to West Africa. Journal of Travel Medicine, 2021, 28, .	3.0	1
120	Neonatal Fungal Infections. , 2012, , 287-302.		1
121	Invasive Yeast Infections. Infectious Disease and Therapy, 2007, , 221-238.	0.0	1
122	Fungal and Parasitic Infections. , 2009, , 113-134.		1
123	Prophylaxis for Candida in the intensive care unit patient. Current Fungal Infection Reports, 2008, 2, 69-73.	2.6	0
124	Can fungal biomarkers be used to improve antifungal therapy in the intensive care unit?. Current Fungal Infection Reports, 2009, 3, 147-151.	2.6	0
125	Don't Pace Right Past the Sink: Electrophysiology Sterility Practices in the Face of Absent Guidelines. Open Forum Infectious Diseases, 2016, 3, .	0.9	0
126	A marginal structural approach to measuring the comparative effectiveness of echinocandins Versus fluconazole therapy for the treatment of adult candidemia (MSG-12). Open Forum Infectious Diseases, 2016, 3, .	0.9	0



#	ARTICLE	IF	CITATIONS
127	Epidemiology and Natural History of Non-Tuberculous Mycobacterial Surgical Sites Infections. Open Forum Infectious Diseases, 2016, 3, .	0.9	0
128	Fungal Diagnostics: A Practical Approach. Current Clinical Microbiology Reports, 2016, 3, 103-110.	3.4	0
129	40 years of medical mycology at JAC. Journal of Antimicrobial Chemotherapy, 2016, 71, 3327-3329.	3.0	0
130	Detecting Infections Rapidly and Easily for Candidemia Trial (DIRECT1): A Prospective, Multicenter Study of the T2Candida Panel. Open Forum Infectious Diseases, 2017, 4, S52-S52.	0.9	0
131	2045. Pitfalls in the Use of MALDI TOF Mass Spectrometry for the Identification of Problematic Yeast Isolates from a Historical Collection. Open Forum Infectious Diseases, 2018, 5, S596-S597.	0.9	0
132	Prevention and Treatment of Yeast and Endemic Fungal Infections. , 2019, , 179-199.		0
133	Measles or Not Measles? That is the Question!. Open Forum Infectious Diseases, 2020, 7, ofaa311.	0.9	0
134	The New Medical Mycology. Infectious Disease Clinics of North America, 2021, 35, xiii-xiv.	5.1	0
135	New Developments in Diagnostics and Management of Invasive Candidiasis. , 0, , 443-448.		0